Episode 49: BIMO Listings

In this QCast episode, Jullia and Tom discuss BIMO listings and their role in FDA inspection readiness. They explain how Bioresearch Monitoring looks at clinical trial conduct, participant protection, data credibility, and the records that support regulatory submissions. The episode also covers common misconceptions, including the idea that BIMO is only a site-level concern, and shows how sponsors can use inspection findings to strengthen oversight before issues become harder to resolve.Key TakeawaysBIMO oversight looks beyond final datasets. It considers how data was collected, reviewed, documented, and supported by source records.BIMO listings can highlight patterns around protocol deviations, informed consent, adverse event reporting, data management, and submission readiness.Good preparation depends on timely data entry, clear query handling, documented decisions, version control, and records that can be retrieved and explained.🔗 Learn More & Get Support: Visit quanticate.com to explore our biometrics services and discover how we can support your next clinical trial. 📝 Episode Notes & Transcript: Find show notes, resources, and a full transcript at quanticate.com/podcast.🔔 Stay Connected: Subscribe to QCast on Apple Podcasts, Spotify, or your favourite platform to never miss an episode.About QuanticateFounded in 1994, Quanticate is a biometrics-focused CRO with over 30 years' experience delivering expert clinical and post-marketing data services worldwide. Specialising in the collection, management, standardisation, analysis, and reporting of data, we support pharma and biotech companies globally with high-quality solutions for clinical development. We specialise in:Clinical Data Capture & ManagementBiostatistics & Statistical ConsultancyStatistical Programming & PK/PD AnalysisMedical Writing & PharmacovigilanceRegulatory & Submission SupportAI & AutomationPost-Marketing Safety & Real-World DataQuanticate is committed to delivering expertise and solutions that drive the success of clinical development worldwide.